IDRI and Medicago announce authorization to initiate a Phase 1 clinical trial for an H5N1 vaccine
The Infectious Disease Research Institute (IDRI), a Seattle-based non-profit research organization that is a leading developer of adjuvants used in vaccines combating infectious disease, and Medicago Inc. (TSX: MDG; OTCQX: ...
Aug 16, 2012
0
0